| Cell line name |
NYH/187/162 |
|---|
| Synonyms |
NYH/187; NYH/ICRF-187-1 |
|---|
| Accession |
CVCL_0B24 |
|---|
| Resource Identification Initiative |
To cite this cell line use: NYH/187/162 (RRID:CVCL_0B24) |
|---|
| Comments |
Selected for resistance to: ChEBI; CHEBI_50223; (+)-dexrazoxane (Cardioxane; ICRF-187).
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:11989; TOP2A; Simple; p.Arg162Gln (c.485G>A); Zygosity=Homozygous; Note=Responsible for resistance to bisdioxopiperazine drugs (PubMed=10416608).
- Mutation; HGNC; HGNC:11998; TP53; Unexplicit; Ex8del14; Zygosity=Unspecified (from parent cell line).
|
|---|
| Disease |
Lung small cell carcinoma (NCIt: C4917)
Small cell lung cancer (ORDO: Orphanet_70573) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_8207 (GLC-2) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
41Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=10416608
Wessel I., Jensen L.H., Jensen P.B., Falck J., Rose A., Roerth M., Nitiss J.L., Sehested M.
Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Cancer Res. 59:3442-3450(1999) PubMed=12044890; DOI=10.1016/S0014-5793(02)02805-3
Wessel I., Jensen L.H., Renodon-Corniere A., Sorensen T.K., Nitiss J.L., Jensen P.B., Sehested M.
Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha.
FEBS Lett. 520:161-166(2002) |
|---|
| Cross-references |
|---|
| Encyclopedic resources |
Wikidata; Q54931215
|
|---|
| Entry history |
|---|
| Entry creation | 10-Apr-2015 |
|---|
| Last entry update | 10-Apr-2025 |
|---|
| Version number | 10 |
|---|
